Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm
Mandate

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

June 11, 2021 Capital Markets and Public M&A Corporate Tax M&A

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market. The prospectus was published on 8 June 2021 and the trading on Nasdaq Stockholm commenced on 11 June 2021.

Sdiptech is a technology group that acquires and develops market-leading niche operations that contribute to creating more sustainable, efficient and safe societies. Sdiptech has approximately SEK 2,000 million in sales and is based in Stockholm.

Vinge’s team has primarily consisted of Dain Hård Nevonen, William Kåge, Anders Sundin Lundberg and Benjamin Vafaeian (Capital Markets and Public M&A), Jesper Lindvall and Eléonore Friberg (M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026